CXCL12 and neoplasm: Therefore, ligand blocking inhibition of ACKR3 such as in the form of specific monoclonal antibodies that inhibit CXCL12 binding and beta-arrestin2 activation could significantly reduce TEC angiogenesis and decrease tumor burden acting as true and specific inhibitors of CXCL12 (29, 53, 57).